Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...
The Consumer Technology Association (CTA) honors Earable® Neuroscience with a CES 2025 Innovation Awards® in Digital Health, ...
Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines ...
Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company focused on marketed products and development candidates, announced its participat ...
Series Novel Combinations (Dopamine Pathway) is under clinical development by Alto Neuroscience and currently in Phase I for Unspecified Psychiatric Disorders.
At CES 2025, Earable Neuroscience introduces FRENZ Brainband's Brainwaves Research platform for pharmas and universities collaborations. Kieu My Doan Earable Inc +1 310-686-8168 email us here Visit us ...
The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...
On a recent visit to Washington DC, Ho sat down with GEN Editorial Director Kevin Davies, PhD, to discuss Denali’s progress ...
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder ...